EPISODE · Apr 19, 2021 · 42 MIN
Filling A Vaccine Void with Cue Biopharma's Dan Passeri, J.D.
from Business Of Biotech · host Matt Pillar
We love to hear from our listeners. Send us a message. CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company's Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company's immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address the scourge of HPV-related head, neck, and other cancers expected in pre-HPV vaccine populations. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
What this episode covers
We love to hear from our listeners. Send us a message. CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company's Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company's immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address the scourge of HPV-related head, neck, and other cancers expected in pre-HPV vacc...
NOW PLAYING
Filling A Vaccine Void with Cue Biopharma's Dan Passeri, J.D.
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m